CTTH
CTT PHARMACEUTICAL HOLDINGS, INC.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- X Jul 31 Short interest jumps 4297.3% to 19.7K
- B Aug 7 to Sep 28 12 days of insider buys: $4.0K by 1 insider, avg $0.0514
- X Aug 14 Short interest falls 74.0% to 5.1K
- X Sep 15 Short interest jumps 106.9% to 10.4K
- X Sep 30 Short interest jumps 75.6% to 18.3K
- B Oct 6 1 insider buy $203.50 at $0.0550
- R Oct 7 CTT Pharmaceutical Holdings' independent auditor, Holt & Patterson,…
- B Oct 15 1 insider buy $114.00 at $0.0570
Signal stack
Where each data set points today.
- InsidersMIXED
1 insider bought $4.3K. No open-market sales. Excludes 1 subscriber-only trade.
- TrendUPTREND
5% above its 50-day average.
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Oct 26, 2026 | 🔒 Fresh data, subscribers only | BUY | |
| Oct 15, 2026 | CTT PHARMACEUTICAL HOLDINGS, INC. CEO | BUY | $114.00 |
| Oct 6, 2026 | CTT PHARMACEUTICAL HOLDINGS, INC. CEO | BUY | $203.50 |
| Sep 28, 2026 | CTT PHARMACEUTICAL HOLDINGS, INC. CEO | BUY | $187.00 |
| Sep 22, 2026 | CTT PHARMACEUTICAL HOLDINGS, INC. CEO | BUY | $454.50 |
| Sep 16, 2026 | CTT PHARMACEUTICAL HOLDINGS, INC. CEO | BUY | $523.20 |
| Sep 10, 2026 | CTT PHARMACEUTICAL HOLDINGS, INC. CEO | BUY | $175.00 |
| Sep 4, 2026 | CTT PHARMACEUTICAL HOLDINGS, INC. CEO | BUY | $479.22 |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Oct 15, 2026SecBot reports
7 filings · 1 bullish · 5 bearish · 1 neutral- NEUTRAL 8-KOct 9, 2026
CTT Pharmaceutical Holdings filed an 8-K with Item 4.01 (Change in Accountant), attaching a letter…
The clean auditor consent letter removes the immediate overhang from the change, but the company remains a development-stage OTC stock with no disclosed revenue or pipeline catalysts. Monitor the…
- BEARISH 8-KOct 7, 2026
CTT Pharmaceutical Holdings' independent auditor, Holt & Patterson, LLC, resigned effective…
Monitor for the appointment of a successor auditor and any subsequent NT 10-K filing if the FY 2026 audit is delayed. The lack of an auditor raises going-concern and delisting risk for this…
- BULLISH 8-KAug 12, 2026
CTT Pharmaceutical Holdings received a continuation-in-part (CIP) patent approval from the USPTO…
The patent broadens CTT's IP moat in oral drug delivery, but the stock trades on OTC with no revenue disclosed. Monitor for any partnership, licensing deal, or product launch announcement that would…
- BEARISH S-1/AJul 24, 2026
CTT Pharmaceutical Holdings filed Amendment No. 6 to its S-1 registration statement, registering…
This is the sixth S-1 amendment for the same ELOC resale registration, indicating a prolonged effort to get the registration effective. Monitor for the SEC declaring the registration effective…
All CTTH filing & press-release reports (7)
- 8-K reportOct 9, 2026
- 8-K reportOct 7, 2026
- 8-K reportAug 12, 2026
- S-1/A reportJul 24, 2026
- S-1/A reportJun 29, 2026
- S-1/A reportJun 16, 2026
- S-1/A reportMay 29, 2026